Immunotherapy of urologic tumors

Broghammer, Elizabeth L.; Ratliff, Timothy L.

doi:10.1016/s1078-1439(01)00151-x

Cited by 13 publications

(8 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment of this disease with cytokines is proving promising, but is still limited, with objective response rates of lower than 20 per cent. 12 Thus, the development of anti-cancer vaccines has rekindled interest in the treatment of RCC, with the aim of activating immune defence mechanisms against the tumour. 13 Vaccination with dendritic cells fused with autologous tumours appears to have potential clinical RCC is a chemotherapyand radiotherapyresistant tumour RCC subtype-specific chromosomal alterations were frequently found RCC is considered to be an immunogenic tumour A number of RCCassociated antigens have been defined via cellular, humoral or in situ immunity benefits with little toxicity, 14 whereas vaccination with immature dendritic cells pulsed with autologous tumour antigens in combination with IL-2 had little benefit for patients with advanced RCC.…”

Section: Renal Cell Carcinomamentioning

confidence: 99%

Detection of renal cell carcinoma-associated markers via proteome- and other 'ome'-based analyses

Seliger

Lichtenfels

Kellner

2003

Briefings in Functional Genomics and Proteomics

View full text Add to dashboard Cite

Proteome analysis has rapidly developed in the post-genome era and is now widely accepted as the complementary technology for genetic profiling. It has been shown to be a powerful tool for studying human diseases and for identifying novel prognostic, diagnostic and therapeutic markers. This review focuses on the identification of new biomarkers and therapeutic targets for renal cell carcinoma using different 'ome'-based technologies.

show abstract

Section: Renal Cell Carcinomamentioning

confidence: 99%

Detection of renal cell carcinoma-associated markers via proteome- and other 'ome'-based analyses

Seliger

Lichtenfels

Kellner

2003

Briefings in Functional Genomics and Proteomics

View full text Add to dashboard Cite

show abstract

“…ccRCC is insensitive to chemotherapy and radiotherapy; therefore, effective post-operative adjuvant therapies are lacking (3). The combined traditional immune therapy using interleukin (IL)-II and interferon does not improve the survival of patients with relapsed or advanced ccRCC (4), with five- and 10-year survival rates of <10% (5). At present, molecular-targeted therapy has been used in post-operative adjuvant therapy for patients with early-stage ccRCC or as palliative treatment for patients with advanced ccRCC (6–12).…”

Section: Introductionmentioning

confidence: 99%

Differential microRNA expression in renal cell carcinoma

Cheng

Wang

et al. 2013

Oncology Letters

View full text Add to dashboard Cite

The present study aimed to detect microRNA expression levels in the tissues and sera of patients with clear cell renal cell carcinoma (ccRCC). The association of microRNA expression with ccRCC clinical pathology was analyzed, and the potential of the microRNAs as ccRCC serum markers and the significance of their expression in the clinical diagnosis, staging, prognosis and selection of new therapeutic targets for ccRCC were discussed. Specific microRNAs were selected according to the associated literature. TaqMan quantitative polymerase chain reaction (qPCR) technology was used to determine the expression levels of selected microRNAs. miR-34a, miR-224 and miR-21 were upregulated, whereas miR-141, miR-149 and miR-429 were downregulated in the ccRCC tissues (P<0.01). The expression of miR-221 and miR-211 was not significant in the ccRCC tissues (P>0.05). miR-34a, miR-21 and miR-224 were upregulated and miR-141 was downregulated in the sera of patients with ccRCC (P<0.01), while the expression of miR-149 and miR-429 was not significant (P>0.05). The serum miR-21 expression levels were significantly correlated with the clinical staging of the patients with ccRCC (P<0.05). miR-34a, miR-21 and miR-224 are upregulated in the tissues and sera of patients with ccRCC, whereas miR-141 is downregulated. miR-21 and miR-141 are associated with ccRCC and are, thus, potential ccRCC serum markers.

show abstract

“…To our knowledge, RCC is insensitive to chemotherapy and radiotherapy; therefore, effective post-operative adjuvant therapies are lacking. 5 The combined traditional immune therapy using interleukin (IL)-II and interferon does not improve survival of patients with relapsed or advanced RCC, 37 with veand 10-year survival rates of <10%. 38 At present, molecular-targeted therapy is used in post-operative adjuvant therapy for patients with early-stage RCC or as palliative treatment for patients with advanced RCC.…”

Section: Discussionmentioning

confidence: 99%